Pancreatic Cancer Therapeutics Market by Type, Product, End-Use

List of Tables

The Pancreatic Cancer Therapeutics Market is projected to reach USD 9.09 billion by 2030 from USD 4.25 billion in 2022, at a CAGR of 9.93% during the forecast period.

Global Pancreatic Cancer Therapeutics Market

KEY MARKET STATISTICS
Base Year [2022]	USD 4.25 billion
Estimated Year [2023]	USD 4.67 billion
Forecast Year [2030]	USD 9.09 billion
CAGR (%)	9.93%

Pancreatic Cancer Therapeutics Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Pancreatic Cancer Therapeutics Market.

Based on Type, market is studied across Endocrine Pancreatic Cancer and Exocrine Pancreatic Cancer. The Exocrine Pancreatic Cancer commanded largest market share of 72.14% in 2022, followed by Endocrine Pancreatic Cancer.

Based on Product, market is studied across Chemotherapy, Gene Therapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy. The Chemotherapy commanded largest market share of 34.33% in 2022, followed by Radiation Therapy.

Based on End-Use, market is studied across Cancer Centers/Clinics, Hospitals, and Research Institutes. The Hospitals commanded largest market share of 42.65% in 2022, followed by Research Institutes.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 43.47% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Pancreatic Cancer Therapeutics Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Pancreatic Cancer Therapeutics Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Pancreatic Cancer Therapeutics Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Pancreatic Cancer Therapeutics Market?

3. What is the competitive strategic window for identifying opportunities in the Pancreatic Cancer Therapeutics Market?

4. What are the latest technology trends and regulatory frameworks in the Pancreatic Cancer Therapeutics Market?

5. What is the market share of the leading vendors in the Pancreatic Cancer Therapeutics Market?

6. Which modes and strategic moves are suitable for entering the Pancreatic Cancer Therapeutics Market?

Product Code: MRR-4342CA32668C

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Pancreatic Cancer Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of pancreatic cancer cases across the world
  - 5.1.1.2. Government initiatives to expand access to pancreatic cancer treatment options
- 5.1.2. Restraints
  - 5.1.2.1. Adverse drug recalls and difficulty in availing reimbursement options
- 5.1.3. Opportunities
  - 5.1.3.1. Research initiatives and advancements to improve the efficacy of pancreatic cancer therapeutics
  - 5.1.3.2. Approvals for pancreatic cancer therapy and orphan drug approvals for cancer treatment
- 5.1.4. Challenges
  - 5.1.4.1. Limitations and complications of pancreatic cancer treatment options and lack of trained medical professionals
5.2. Market Segmentation Analysis
- 5.2.1. Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
- 5.2.2. Product: Expanding number of approvals for chemotherapy treatment options
- 5.2.3. End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
5.3. Market Trend Analysis
- 5.3.1. Advancements in pancreatic cancer therapeutics in Americas region due to strong presence of key players and supportive regulatory landscape
- 5.3.2. Collaborative R&D activities by cancer research organization and improved support for clinical trials of novel therapies to elevate the advancements in pancreatic cancer therapeutics in the Asia-Pacific
- 5.3.3. Concerted efforts of researchers, funding agencies, and regulatory bodies catalyzing to delivering novel pancreatic cancer therapeutic solutions across EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Pancreatic Cancer Therapeutics Market, by Type

6.1. Introduction
6.2. Endocrine Pancreatic Cancer
6.3. Exocrine Pancreatic Cancer

7. Pancreatic Cancer Therapeutics Market, by Product

7.1. Introduction
7.2. Chemotherapy
7.3. Gene Therapy
7.4. Immunotherapy
7.5. Radiation Therapy
7.6. Surgery
7.7. Targeted Therapy

8. Pancreatic Cancer Therapeutics Market, by End-Use

8.1. Introduction
8.2. Cancer Centers/Clinics
8.3. Hospitals
8.4. Research Institutes

9. Americas Pancreatic Cancer Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Pancreatic Cancer Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Pancreatic Cancer Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Merger & Acquisition
  - 12.3.1.1. PanCAN Announces New & Advanced Research Investment
  - 12.3.1.2. TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
  - 12.3.1.3. Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
  - 12.3.1.4. Leap Therapeutics Acquires Flame Biosciences
  - 12.3.1.5. Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
- 12.3.2. Agreement, Collaboration, & Partnership
  - 12.3.2.1. Prestige Biopharma and Imagion Biosystems Sign Partnership Agreement to Develop Early Pancreatic Cancer Diagnosis Platform
- 12.3.3. New Product Launch & Enhancement
  - 12.3.3.1. GenesisCare Launches ViewRay MRIdian MRI-Guided Radiation Therapy System at Lee Health Regional Cancer Center
- 12.3.4. Investment & Funding
  - 12.3.4.1. Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
  - 12.3.4.2. USD 3 Million National Grant to Fund Pancreatic Cancer Study
  - 12.3.4.3. Faeth Therapeutics Raises USD 47 million to Advance Clinical Trials for Cancer
- 12.3.5. Award, Recognition, & Expansion
  - 12.3.5.1. Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients
  - 12.3.5.2. Lisata Receives Orphan Drug Designation For Pancreatic Cancer Therapy
  - 12.3.5.3. FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for NRG1+ Pancreatic Cancer
  - 12.3.5.4. FDA Clears TME Pharma's IND for Pancreatic Cancer Therapy Trial
  - 12.3.5.5. AstraZeneca-Merck's Lynparza Wins EU Approval for Pancreatic Cancer

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abbvie Inc.
- 13.1.2. Amgen Inc.
- 13.1.3. Ascentage Pharma Group
- 13.1.4. Astellas Pharma Inc.
- 13.1.5. AstraZeneca PLC
- 13.1.6. Bristol-Myers Squibb Company
- 13.1.7. C.H. Boehringer Sohn AG & Co. KG
- 13.1.8. Carl Zeiss AG
- 13.1.9. Carrick Therapeutics Limited
- 13.1.10. Cipla Limited
- 13.1.11. Dr. Reddy's Laboratories Ltd.
- 13.1.12. Eli Lilly and Company
- 13.1.13. F. Hoffmann-La Roche AG
- 13.1.14. Faeth Therapeutics, Inc.
- 13.1.15. FUJIFILM Holdings Corporation
- 13.1.16. GE HealthCare Technologies, Inc.
- 13.1.17. GenesisCare
- 13.1.18. GlaxoSmithKline PLC
- 13.1.19. Hetero Healthcare Limited
- 13.1.20. ImmunityBio, Inc.
- 13.1.21. Innovent Biologics Inc.
- 13.1.22. Johnson & Johnson Services, Inc.
- 13.1.23. Lupin Limited
- 13.1.24. Merck & Co., Inc.
- 13.1.25. Mitsubishi Heavy Industries, Ltd.
- 13.1.26. NGM Biopharmaceuticals, Inc.
- 13.1.27. NovalGen
- 13.1.28. Novartis AG
- 13.1.29. PanTher Therapeutics, Inc.
- 13.1.30. Pfizer, Inc.
- 13.1.31. RenovoRx, Inc.
- 13.1.32. Sun Pharmaceutical Industries Ltd.
- 13.1.33. Teva Pharmaceutical Industries Ltd.
- 13.1.34. Zentalis Pharmaceuticals, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing